Clinical Trials Logo

Amaurosis Fugax clinical trials

View clinical trials related to Amaurosis Fugax.

Filter by:
  • None
  • Page 1

NCT ID: NCT03753893 Completed - Macular Edema Clinical Trials

Ocular Manifestations in Rheumatic Diseases

Start date: May 1, 2013
Phase:
Study type: Observational

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

NCT ID: NCT01645306 Completed - Stroke Clinical Trials

Revacept in Symptomatic Carotid Stenosis

RevaceptCS02
Start date: March 8, 2013
Phase: Phase 2
Study type: Interventional

Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone. Patients receive a single dose of trial medication by intravenous infusion for 20 minutes. Patients are followed up one and three days after treatment, at 3 months and by a telephone interview at 12 months.

NCT ID: NCT01445613 Active, not recruiting - Stroke Clinical Trials

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

CANOPY
Start date: October 2011
Phase: N/A
Study type: Interventional

The objective of the CANOPY trial is to assess the continued safety and effectiveness of the RX Acculink Carotid Stent System under commercial use in subjects at standard risk for adverse events from Carotid Endarterectomy (CEA) enrolled by physicians with a range of carotid stenting experience.